Radiation-Induced Targeted Nanoparticle-Based Gene Delivery for Brain Tumor Therapy

Area of Science:

• Oncology
• Nanotechnology
• Immunotherapy

Background:

• Targeted therapy for programmed cell death ligand-1 (PD-L1) shows promise but is less effective against gliomas.
• Effective glioma treatment requires central nervous system delivery with minimal side effects.
• Glioblastoma is an aggressive brain tumor with limited therapeutic options.

Purpose of the Study:

• To develop a novel nanoparticle delivery system for combined glioblastoma therapy.
• To investigate the synergistic effect of radiation therapy and targeted immunotherapy.
• To enhance the delivery of small interfering RNAs (siRNAs) targeting epidermal growth factor receptor (EGFR) and PD-L1.

Main Methods:

• Development of cyclic peptide iRGD-conjugated solid lipid nanoparticles (SLNs) for siRNA delivery.
• Utilizing low-dose radiation to prime the brain tumor microenvironment for enhanced nanoparticle uptake.
• Evaluating the efficacy of combined radiation and targeted SLN therapy in a glioblastoma mouse model using bioluminescence imaging.

Main Results:

• Low-dose radiation enhanced the uptake of targeted SLNs into the brain tumor region.
• The combined therapy led to significant downregulation of both PD-L1 and EGFR.
• Radiation therapy followed by targeted SLN administration significantly inhibited glioblastoma growth and prolonged mouse survival.

Conclusions:

• A combined approach of radiation therapy and iRGD-conjugated SLN delivery offers an effective strategy for glioblastoma treatment.
• This method enhances nanoparticle uptake and enables combined EGFR inhibition and immunotherapy.
• The developed approach shows potential for treating other aggressive tumor types.